Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-VEGF”

485 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 485 results

Not applicableStudy completedNCT02279537
What this trial is testing

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Who this might be right for
Wet Macular Degeneration
Bayer 593
Large-scale testing (Phase 3)Study completedNCT00470678
What this trial is testing

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Who this might be right for
Choroidal NeovascularizationAge-Related Macular Degeneration
Novartis 95
Not applicableNot Yet RecruitingNCT06243406
What this trial is testing

Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization

Who this might be right for
Choroidal Neovascularization
Beijing Hospital 80
Not applicableUnknownNCT01303276
What this trial is testing

Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)

Who this might be right for
Central Retinal Vein Occlusion
University of Toronto 30
Not applicableUnknownNCT00640640
What this trial is testing

The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)

Who this might be right for
Neovascular Age Related Macular Degeneration
Sheba Medical Center 60
Not applicableStudy completedNCT05472376
What this trial is testing

Real-Life Study in Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema
Kocaeli University 854
Post-approval studies (Phase 4)Ended earlyNCT02570789
What this trial is testing

Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy

Who this might be right for
Clear-cell Metastatic Renal Cell Carcinoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 90
Not applicableStudy completedNCT01446224
What this trial is testing

Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

Who this might be right for
Carcinoma, Renal Cell
GlaxoSmithKline 1
Large-scale testing (Phase 3)Study completedNCT01311960
What this trial is testing

Topical Bevacizumab for Preventing Recurrent Pterygium

Who this might be right for
PterygiumBevacizumabVEGF+1 more
Chulalongkorn University 24
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Not applicableStudy completedNCT03509623
What this trial is testing

Blood Coagulation Parameters in Patients Receiving Intravitreal Aflibercept for Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
University Hospital of Patras 47
Not applicableStudy completedNCT02979665
What this trial is testing

Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 51
Testing effectiveness (Phase 2)Ended earlyNCT01025232
What this trial is testing

Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

Who this might be right for
Age Related Macular DegenerationChoroidal Neovascular MembraneSubfoveal Neovascular Age-Related Macular Degeneration+2 more
David M. Brown, M.D. 88
Testing effectiveness (Phase 2)Active Not RecruitingNCT02884648
What this trial is testing

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Who this might be right for
Malignant Neoplasms of Female Genital OrgansOvarian CancerFallopian Tube Cancer+1 more
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)Study completedNCT00025233
What this trial is testing

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Who this might be right for
Cervical Squamous Cell CarcinomaRecurrent Cervical Cancer
National Cancer Institute (NCI) 50
Large-scale testing (Phase 3)WithdrawnNCT04697953
What this trial is testing

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals
Not applicableUnknownNCT05529589
What this trial is testing

Comparison of Restoration in Vitreous Hemorrhage Patients With DME After or Not Removing Inner Limiting Membrane

Who this might be right for
Macular Edema Due to Diabetes MellitusVitreous Hemorrhage
Second Affiliated Hospital, School of Medicine, Zhejiang University 120
Large-scale testing (Phase 3)WithdrawnNCT03784443
What this trial is testing

Combined Ranibizumab and Iluvien for Diabetic Macular Oedema

Who this might be right for
Diabetic Macular EdemaDiabetes
Imperial College London
Not applicableUnknownNCT01655589
What this trial is testing

VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

Who this might be right for
Macular Degeneration
Institute of Vision, Brasil 74
Early research (Phase 1)Study completedNCT00454649
What this trial is testing

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Who this might be right for
Neoplasms
Pfizer 102
Load More Results